Guggenheim Capital LLC Trims Stake in Repligen Co. (NASDAQ:RGEN)

Guggenheim Capital LLC reduced its position in shares of Repligen Co. (NASDAQ:RGEN) by 6.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,575 shares of the biotechnology company’s stock after selling 111 shares during the period. Guggenheim Capital LLC’s holdings in Repligen were worth $227,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in RGEN. Groupama Asset Managment lifted its holdings in shares of Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock worth $58,142,000 after acquiring an additional 400,680 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Repligen in the 4th quarter worth approximately $52,492,000. Allspring Global Investments Holdings LLC grew its position in shares of Repligen by 79.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock worth $65,395,000 after buying an additional 203,011 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock worth $145,508,000 after buying an additional 191,439 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Repligen in the 4th quarter worth approximately $24,034,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on RGEN shares. HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Canaccord Genuity Group dropped their price target on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research report on Wednesday, April 16th. Evercore ISI assumed coverage on Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price target on the stock. TD Cowen assumed coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. Finally, StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Monday. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $176.82.

Repligen Stock Down 0.8 %

RGEN stock opened at $143.63 on Tuesday. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The business has a fifty day moving average price of $139.66 and a 200-day moving average price of $145.97. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market capitalization of $8.06 billion, a P/E ratio of -281.63, a P/E/G ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Equities analysts forecast that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.